Cytosorbents Still Riding Wave from Analysts’ Recommendation (CTSO)

Shares of Cytosorbents (OTC: CTSO) continued to ride a wave of enthusiasm from a “Buy” recommendation put out last week by analysts at Brean Murray. Cytosorbents is preparing for its European launch of a breakthrough device, Cytosorb, which removes blood toxins. The analysts think the company holds great potential since there are no effective treatments for severe sepsis. Regulators in Europe approved the product before the release of final clinical trial results.

The recommendation moved the stock higher by 30% since the last week. Shares tacked on a gain of 10% today on volume greater than its daily average. The stock opened unchanged at $0.133, which also represented the low for the day. The high print for the session occurred in the second hour of trading when the stock traded for $0.152. Shares ended the day up a penny and a third to close at $0.146. About 1.8 million shares exchanged hands compared to an average day of 495,000 shares.

Over the last 52-weeks, the stock has traded in a range from just under $0.30 to a low of $0.065. The high trade for shares of Cytosorbents happened almost 11 months ago on a day when volume soared to nearly 10 million. Nine months after making an annual high, the stock touched bottom and it has been drifting higher since.

On June 20, 2012, the company announced the formation of a core sales group for the official launch of Cytosorb in Germany. On the same day, the company noted that CFO David Lamadrid had left Cytosorbents.

In March of this year, Cytosorbents received approval from European Union regulators for Cytosorb. Clinical trials showed the ability of the device to reduce circulating plasma cytokine levels during the treatment of patients with sepsis or respiratory failure. The trials involved 300 patients. The stock rallied sharply on the news but failed to keep buyers interested longer than one day. Watching the stock gain now for several days following the initiation of a “Buy” rating, traders may be wondering if the move over the last several days finally means shares are ready to go even higher.

Stock promotion and newsletter activity for Cytosorbents has been sparse. A total of three promotions from a year ago can be viewed on and additional notes can be found at

No references about Cytosorbents were found on Twitter today, but several comments were made about the company earlier this week. @Serious Traders mentioned the breakthrough technology on July 30, 2012, and @Seeking Alpha mentioned the company on July 29.

Cytosorbents is a therapeutic device company primarily focusing on the development and commercialization of blood purification devices.

For consideration of being featured on WallstreetPR, contact:

Please make sure to read and completely understand our disclaimer at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at

Published by Alan Masterson

Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email ( or his Google+ page (